2-(3,5-双(三氟甲基)苯基)乙醛 | 369625-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(3,5-双(三氟甲基)苯基)乙醛
• 英文名称: 3,5-ditrifluoromethylphenylacetaldehyde
• 英文别名: 2-(3,5-Bis(trifluoromethyl)phenyl)acetaldehyde；2-[3,5-bis(trifluoromethyl)phenyl]acetaldehyde
• CAS: 369625-84-3
• 化学式: C₁₀H₆F₆O
• 分子量: 256.147
• InChiKey: TXJWMEJYJVYJPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 海关编码：
  2913000090

文献信息

• [EN] ANTIDIABETIC SPIROCHROMAN COMPOUNDS<br/>[FR] COMPOSÉS DE SPIROCHROMANE ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2018118670A1

  公开（公告）日：2018-06-28

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能在治疗、预防和抑制由G蛋白偶联受体40介导的疾病方面有用。本发明的化合物可能在治疗2型糖尿病以及与该疾病常相关的病症，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症方面有用。
• Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
  申请人：Wang Yanjun Eric

  公开号：US20070293548A1

  公开（公告）日：2007-12-20

  Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.

  提供了用于治疗炎症性疾病和免疫紊乱的组合物及使用组合物的方法。公开了一种烯丙胺化合物，它们是半胱氨酸敏感胺氧化酶（SSAO）和/或血管粘附蛋白1（VAP-1）的抑制剂。这些化合物在抑制炎症和炎症反应方面具有治疗效用，并可用于治疗多发性硬化症和中风等多种疾病。
• [EN] POLYMORPHIC FORM OF A TACHYKININ RECEPTOR ANTAGONIST<br/>[FR] FORME POLYMORPHE D'UN ANTAGONISTE DE RECEPTEUR DE TACHYKININE
  申请人：MERCK & CO INC

  公开号：WO2001032656A1

  公开（公告）日：2001-05-10

  This invention is concerned with a novel polymorphic forms of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethyl-amino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine hydrochloride which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic forms have advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine hydrochloride in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.

  本发明涉及一种新型多态形式的化合物2-(R)-(1-(R)-(3,5-双三氟甲基苯基)乙氧基)-4-(5-(二甲氨基)甲基-1,2,3-三唑-4-基)甲基-3-(S)-(4-氟苯基)吗啡啡曲马琳盐酸盐，该化合物是一种缓释激肽受体拮抗剂，可用于治疗或预防中枢神经系统疾病、炎症性疾病、疼痛或偏头痛、哮喘和呕吐等疾病。此多态形式相对于已知的2-(R)-(1-(R)-(3,5-双三氟甲基苯基)乙氧基)-4-(5-(二甲氨基)甲基-1,2,3-三唑-4-基)甲基-3-(S)-(4-氟苯基)吗啡啡曲马琳盐酸盐的其他形式具有热力学稳定性和适合制药配方的优点。
• [EN] PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3A)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-3-(4-FLUOROPHENYL)-1,4-OXAZINE<br/>[FR] PROCEDE DE SYNTHESE DE (2R, 2-ALPHA-R, 3A)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-3-(4-FLUOROPHENYL)-1,4-OXAZINE
  申请人：MERCK & CO INC

  公开号：WO2001094324A1

  公开（公告）日：2001-12-13

  The present invention is concerned with novel processes for the preparation of (2R, 2-alpha-R, 3a)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-1,4-oxazine. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity.

  本发明涉及一种新型制备 (2R, 2-alpha-R, 3a)-2-[1-[3,5-双三氟甲基苯基]乙氧基-3-(4-氟苯基)-1,4-噁唑的方法。该化合物可作为合成具有药理活性化合物的中间体。
• [EN] CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] DERIVES DE CYCLOHEXYLE ET LEUR UTILISATION COMME AGENTS THERAPEUTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2001087838A1

  公开（公告）日：2001-11-22

  The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R?1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b¿ are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

  本发明涉及公式（I）的化合物，其中环A是苯环或吡啶环；X代表从公式（a）、（b）、（c）、（d）和（e）组成的链连接物；R?1、R2、R3、R4、R5、R6、R7、R13、R14、R15、R16、R17、R21a和R21b¿如本文所定义。该化合物特别适用于治疗或预防抑郁症、焦虑症、疼痛、炎症、偏头痛、呕吐或带状疱疹后神经痛。